Improving Calgary’s Methamphetamine Intoxication Management in Emergency Departments: Experiences and Perceptions of Patients, Allied Healthcare Providers, and Frontline Community Staff
Summary
Within the city of Calgary, and the province of Alberta, there has been a large increase in emergency department visits related to methamphetamine type drugs. Using methamphetamines can cause intoxication and the effects of this can include: increased energy, alertness, extreme happiness, enhanced sexual activity, long periods without sleep, an altered understanding of reality, and possibly anger, aggression or psychosis. In cases where people are intoxicated by methamphetamines and require immediate medical care, it is often difficult to transport these people to the emergency department, protect them from hurting themselves or others, or to provide care for these people. This may cause methamphetamine patients to receive poor care or feeling poorly about themselves or being hurt. It also may lead to care providers being hurt or feeling unhappy about their encounters with these patients.
This project is designed to gather the points of view, feelings and experiences of both providers (who either transport, protect or care for people who are intoxicated by methamphetamines during emergency department visits) and from methamphetamine patients themselves. We will give providers an online survey with both questions aimed to better understand how they feel about methamphetamine care in Calgary. We will also be interviewing past-patients of these methamphetamine-related emergency department visits about their perspectives and experiences about their care in Calgary. Our findings will be reported to Alberta Health Services to help them as they begin to update their management strategies of patient intoxicated by methamphetamines in order to keep both patients and staff safer and happier.
This study will possibly benefit people who use methamphetamines and providers who encounter them in the city of Calgary. With improved strategies based on findings from this study and others, the emergency department staff, other providers and patients will be safer and feel better, leading to a higher quality of life for everyone. These results may also be used to influence the way methamphetamine intoxication is managed across Canada and potentially be used to benefit health systems in other countries.
Eligibility
Eligible ages: 18 to 100
Accepts healthy participants: Yes
Inclusion criteria:
Two groups of people are eligible for this study:
1. People who are providers of care (like nurse, physicians, police, paramedics, hospital security staffs) who have encounter patients intoxicated by methamphetamines in Calgary during the past 5 years.
2. Patients who have presented at an emergency department in Calgary while intoxicated by methamphetamines in the past 5 years.
All participants must also be:
1. They must be 18 years or older
2. Be able to fluently speak English
3. Not be in a mental state or distress or psychosis.
Exclusion criteria:
1. Participants who do not have experiences within the City of Calgary Alberta.
2. Participants whose experiences are over 5 years old.
3. Participants who do not have experiences with emergency departments.
4. Participants who do not have experiences involving methamphetamines intoxication
5. People who are under 18 years old
6. People who do no fluently speak English
7. People in a mental state or distress or psychosis.
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
Interested participants may contact research coordinator Dylan Viste at dylan.viste@ucalgary.ca who will be able to answer further questions and provide the next steps to participate.
Principal investigator:
Sumantra Monty Ghosh
Clinical trial:
No
REB-ID:
REB22-0326